MEDICLIN (MED) AI Stock Analysis

• Market Cap: €146.30M
• Dividend Yield: 1.33%
• Average Volume (3M): 7.68K
• Price to Earnings (P/E): 5.6
• Beta (1Y): 0.14
• Revenue Growth: 1.26%
• EPS Growth: N/A
• Country: DE
• Employees: 7,292
• Sector: Healthcare
• Sector Strength: 41
• Industry: Medical - Care Facilities
• EPS (TTM): N/A
• Shares Outstanding: 47,500,000
• 10 Day Avg. Volume: 12,732
• 30 Day Avg. Volume: 7,682
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €3.50
• Price Target Upside: 17.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 72 Outperform
• Price Target: €3.50 ▲(17.45% Upside)

MEDICLIN's strong valuation metrics and positive technical indicators significantly contribute to its overall attractiveness. Financial performance is solid, though high leverage remains a concern. The absence of earnings call and corporate events data limits further insights.

MEDICLIN Business Overview & Revenue Model

Company Description

MEDICLIN Aktiengesellschaft operates hospitals in Germany. The company operates through Post-Acute, Acute, and Other Activities segments. It offers medical services in the areas of neurology, psychosomatics, orthopaedics, internal medicine, cardiology, oncology, geriatrics, psychiatry, surgery, nursing care, and others. The company also provides services in the areas of ENT and acute outpatient services. As of December 31, 2021, it owned 34 clinics, 7 nursing care facilities, and 11 medical care centres with a total capacity of 7,831 beds and 482 nursing places in 11 German federal states. The company is headquartered in Offenburg, Germany.

How the Company Makes Money

MEDICLIN generates revenue through multiple streams, including patient care services, which encompass hospital stays, outpatient treatments, and rehabilitation programs. The company typically bills patients and their insurance providers for these services, creating a significant revenue source. Additionally, MEDICLIN may engage in partnerships with insurance companies to provide specific healthcare plans, further diversifying its income. Other revenue streams may include specialized services and programs that cater to specific medical needs, as well as potential government funding for public health initiatives. Partnerships with pharmaceutical or medical device companies for clinical trials and research can also contribute to its earnings.

MEDICLIN Financial Statement Overview

Summary

MEDICLIN shows improving profitability with a positive net profit margin and strong operational efficiency. However, the high debt-to-equity ratio indicates significant leverage risks, necessitating cautious debt management.

Income Statement

MEDICLIN has shown a consistent increase in gross profit margin, highlighting effective cost management, while the net profit margin improved notably in the latest period, turning positive after prior losses. Revenue growth has been moderate, and the recent EBIT and EBITDA margins are strong, indicating operational efficiency. However, past volatility in net income suggests some instability.

Balance Sheet

The company's debt-to-equity ratio remains high, reflecting significant leverage which could pose financial risks. However, the improving return on equity and stable equity ratio suggest that MEDICLIN is effectively using its equity base to generate profits. The balance sheet shows a need for cautious debt management to ensure financial stability.

Cash Flow

Operating cash flow has been robust, consistently exceeding net income, indicating strong cash generation from operations. The free cash flow to net income ratio is favorable, showing efficient capital expenditure management. There is notable free cash flow growth, demonstrating improved liquidity, although careful monitoring is advisable to sustain this trend.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	748.80M	730.10M	704.70M	673.10M	659.90M
Gross Profit	623.00M	594.60M	571.90M	551.00M	547.20M
EBITDA	106.41M	101.27M	91.80M	85.43M	76.84M
Net Income	24.84M	-10.78M	9.44M	1.46M	-9.00M
Balance Sheet
Total Assets	905.91M	880.50M	916.11M	881.24M	887.46M
Cash, Cash Equivalents and Short-Term Investments	107.56M	115.29M	88.04M	133.48M	100.44M
Total Debt	464.13M	479.82M	502.67M	439.96M	486.97M
Total Liabilities	683.17M	684.47M	706.79M	698.22M	710.62M
Stockholders Equity	222.51M	195.92M	209.21M	183.28M	177.16M
Cash Flow
Free Cash Flow	35.88M	40.43M	8.62M	64.96M	92.91M
Operating Cash Flow	80.57M	78.00M	34.64M	81.97M	118.69M
Investing Cash Flow	-15.13M	-9.51M	-6.24M	-7.09M	-8.60M
Financing Cash Flow	-73.16M	-45.48M	-56.17M	-55.26M	-46.50M

MEDICLIN Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.98
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Positive. The current price of 2.98 is above the 20-day moving average (MA) of 2.96, below the 50-day MA of 2.98, and above the 200-day MA of 2.78, indicating a bullish trend. The MACD of 0.02 indicates Negative momentum. The RSI at 51.90 is Neutral, neither overbought nor oversold. The STOCH value of 52.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:MED.

MEDICLIN Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MED	72 Outperform	€146.30M	5.61	12.45%	1.33%	1.26%	―
Sector *	60 Neutral	HK$18.32B	5.55	-4.00%	3.32%	9.92%	-18.97%
0NQH	―	€763.10M	20.25	2.93%	―	―	―
MAK	―	€25.37M	―		―	―	―
LIK	75 Outperform	€106.20M	33.35	18.60%	―	0.76%	-8.38%
HAEK	―	€52.62M	―		―	―	―
M12	72 Outperform	€255.14M	15.82	14.61%	3.57%	7.23%	58.37%